

**esomeprazole intravenous formulation (Nexium IV<sup>®</sup>) (No. 124/04)**  
**AstraZeneca**

**Summary of Advice**

11 October 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following a full submission.

Intravenous esomeprazole (Nexium IV<sup>®</sup>) is accepted for use within NHS Scotland for the treatment of gastroesophageal reflux disease in patients with esophagitis and/or severe symptoms of reflux as an alternative to oral therapy when oral intake is not appropriate.

Intravenous esomeprazole seems to be as effective as oral esomeprazole in terms of gastric acid suppression and healing of erosive oesophagitis. However comparisons with other IV proton pump inhibitors are restricted to pre-clinical studies. Esomeprazole has similar acquisition costs to other IV proton pump inhibitors.

Professor David H Lawson  
Chairman